Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Ltd has announced the closure of its trading window for designated persons. This closure is in anticipation of the declaration of Unaudited Standalone Financial Results for the quarter and nine months ended September 30, 2026. The trading window will be shut from October 1, 2026, and will reopen 48 hours after the results are officially announced to the stock exchanges. This measure is in line with the company's Code of Conduct to prevent insider trading.

Sanofi Consumer Healthcare India Ltd announced that its Board of Directors, in a meeting held on July 28, 2026, has approved the unaudited financial results for the quarter and half-year ended June 30, 2026. The company has submitted these results along with the Limited Review Report from statutory auditors, Price Waterhouse & Co Chartered Accountants LLP, as per SEBI Listing Regulations. The results will be published in newspapers and made available on the company's investor website. The board meeting commenced at 4:00 p.m. and concluded at 6:00 p.m.

Sanofi Consumer Healthcare India Ltd announced its unaudited financial results for the quarter and half-year ended June 30, 2026. The Board of Directors approved these results at a meeting held on July 28, 2026. The company has submitted the results along with a Limited Review Report from its statutory auditors, Price Waterhouse & Co Chartered Accountants LLP, as per SEBI Listing Regulations. The results will be published in newspapers and made available on the company's investor relations website.

Sanofi Consumer Healthcare India Ltd announced that its Board of Directors met on Tuesday, 28th July 2026, to consider and approve the Unaudited Financial Results for the quarter and half-year ended 30th June 2026. The company has submitted these results, along with the Limited Review Report from its statutory auditors, Price Waterhouse & Co Chartered Accountants LLP, to the stock exchanges. The financial results will be published in newspapers and made available on the company's investor relations website.

Sanofi Consumer Healthcare India Ltd has announced that its Board of Directors will convene on July 28, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the quarter and half-year ended June 30, 2026. Additionally, the company has informed that the trading window for designated persons will remain closed from July 1, 2026, to July 30, 2026, inclusive, in accordance with its internal code of conduct regarding the publication of these financial results.

Sanofi Consumer Healthcare India Ltd announced the appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP (PwC) as its new Statutory Auditors. This appointment, approved by shareholders at the 3rd Annual General Meeting held on June 26, 2026, fills a casual vacancy caused by the resignation of M/s. Kalyaniwalla & Mistry LLP. PwC will serve until the conclusion of the 3rd AGM and then for a subsequent term of five consecutive years, concluding at the 8th AGM in 2031. PwC is a well-established firm with extensive experience in assurance and auditing services.

Sanofi Consumer Healthcare India Ltd has announced the closure of its trading window to comply with its Insider Trading Code. This closure is in preparation for the declaration of the Unaudited Standalone Financial Results for the quarter and half-year ending June 30, 2026. The trading window will be shut from July 1, 2026, and will reopen 48 hours after the results are officially announced to the stock exchanges. This measure is standard practice to prevent potential insider trading activities.

Sanofi Consumer Healthcare India Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the Financial Year ended December 31, 2025. The report, which is part of the Annual Report, details the company's operations, employee data, and market presence. Key disclosures include 100% turnover from Drugs and Pharmaceuticals, operations serving 29 national and 4 international markets, and a workforce of 518 employees and 79 workers. The company also reported a 19% contribution from exports to its total turnover.

Sanofi Consumer Healthcare India Ltd has filed its Annual Report for the Financial Year 2025. The report includes the Notice of the 3rd Annual General Meeting (AGM) scheduled for June 26, 2026, to be held via Video Conferencing. Key dates for e-voting, remote e-voting, and book closure have been announced. The dividend payment date is set for July 9, 2026. The Annual Report details the company's performance highlights, business strengths, strategy, portfolio, CSR initiatives, and corporate governance for the fiscal year ended December 31, 2025.

Sanofi Consumer Healthcare India Ltd has announced its 3rd Annual General Meeting (AGM) scheduled for Friday, June 26, 2026, at 3:00 PM IST, to be conducted via Video Conferencing. Key agenda items include the adoption of the Annual Audited Standalone Financial Statements for the year ended December 31, 2025, the declaration of a final dividend of ₹75 per equity share, the re-appointment of Mr. Stanislas Camart as Director, and the appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as Statutory Auditors for a term of five years. The meeting will also address the filling of a casual vacancy for Statutory Auditors.